Abstract |
LY355703 is a synthetic product structurally related to the cryptophycin family isolated from the blue-green algae, which exerts a potent destabilization of microtubules during mitosis. This study was performed to determine the activity of LY355703 in patients with platinum-resistant advanced ovarian cancer and to characterize its toxicity profile. Twenty-six patients were enrolled in this study. Resistant disease was defined as a platinum-free interval of <6 months from primary treatment or rechallenge. LY355703 (1.5 mg/m(2)) was administered intravenously on days 1 and 8, every 3 weeks, infused over 2 h. From 24 patients evaluable for response, three partial responses (12.5%) and seven disease stabilizations were registered (29.2%), for an overall clinical benefit of 41.7%. Fourteen patients (58.3%) experienced a progression of the disease during treatment. Among the 25 patients evaluable for toxicity, two episodes of grade 3 anemia (8%); one, grade 3 thrombocytopenia (4%); one, grade 4 elevation of creatinine (4%); and one, grade 3 hyperbilirubinemia (4%) were reported. LY355703 has a modest activity in patients with platinum-resistant advanced ovarian cancer. Nevertheless, the considerable rate of disease stabilization in the absence of serious adverse events in this poor-prognosis study population suggests that this novel cryptophycin may deserve further investigation in this setting.
|
Authors | G D'Agostino, J del Campo, B Mellado, M A Izquierdo, T Minarik, L Cirri, L Marini, J L Perez-Gracia, G Scambia |
Journal | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
(Int J Gynecol Cancer)
2006 Jan-Feb
Vol. 16
Issue 1
Pg. 71-6
ISSN: 1048-891X [Print] England |
PMID | 16445613
(Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Depsipeptides
- Lactams
- Lactones
- Platinum
- cryptophycin 52
|
Topics |
- Adult
- Aged
- Depsipeptides
(administration & dosage)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Female
- Humans
- Infusions, Intravenous
- Lactams
(administration & dosage)
- Lactones
(administration & dosage)
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Invasiveness
(pathology)
- Neoplasm Staging
- Ovarian Neoplasms
(drug therapy, mortality, pathology)
- Platinum
(therapeutic use)
- Prognosis
- Risk Assessment
- Single-Blind Method
- Survival Analysis
- Treatment Outcome
|